

ACYCLOVIR OINT (CCHP2017)

Products Affected

Step 2:

- *acyclovir 5 % topical ointment*

Details

Criteria	Step Therapy requires trial of one (1) of the following: oral generic acyclovir, oral generic famciclovir, oral generic valacyclovir.
----------	---

ALPHAGAN (CCHP2017)

Products Affected

Step 2:

- ALPHAGAN P 0.1 % EYE DROPS

Details

Criteria	Step Therapy requires trial of brimonidine 0.15%.
----------	---

ANTIDEPRESSANT_NVT 2017

Products Affected

Step 2:

- DESVENLAFAXINE ER 100 MG
TABLET,EXTENDED RELEASE 24 HR
- DESVENLAFAXINE ER 50 MG
TABLET,EXTENDED RELEASE 24 HR
- DESVENLAFAXINE FUMARATE ER
100 MG TABLET, EXTENDED
RELEASE 24 HR
- DESVENLAFAXINE FUMARATE ER
50 MG TABLET, EXTENDED
RELEASE 24 HR
- *duloxetine 40 mg capsule, delayed release*
- EMSAM 12 MG/24 HR
TRANSDERMAL 24 HOUR PATCH
- EMSAM 6 MG/24 HR TRANSDERMAL
24 HOUR PATCH
- EMSAM 9 MG/24 HR TRANSDERMAL
24 HOUR PATCH
- FETZIMA 120 MG
CAPSULE,EXTENDED RELEASE
- FETZIMA 20 MG (2)-40 MG (26)
CAPSULE,EXTENDED RELEASE,24
HR,DOSE PACK
- FETZIMA 20 MG
CAPSULE,EXTENDED RELEASE
- FETZIMA 40 MG
CAPSULE,EXTENDED RELEASE
- FETZIMA 80 MG
CAPSULE,EXTENDED RELEASE
- *fluvoxamine er 100 mg capsule, extended
release 24 hr*
- *fluvoxamine er 150 mg capsule, extended
release 24 hr*
- MARPLAN 10 MG TABLET
- TRINTELLIX 10 MG TABLET
- TRINTELLIX 20 MG TABLET
- TRINTELLIX 5 MG TABLET
- VIIBRYD 10 MG (7)-20 MG (23)
TABLETS IN A DOSE PACK
- VIIBRYD 10 MG TABLET
- VIIBRYD 20 MG TABLET
- VIIBRYD 40 MG TABLET

Details

Criteria	Step Therapy requires trial of one of the following generic SSRI's in previous 120 days: escitalopram, sertraline, fluoxetine, citalopram, paroxetine, Paxil oral solution, or fluvoxamine. If request is for duloxetine, step not required for diabetic peripheral neuropathy, fibromyalgia, or chronic musculoskeletal pain.
-----------------	--

ARICEPT 23_NVT 2015

Products Affected

Step 2:

- *donepezil 10 mg disintegrating tablet*
- *donepezil 5 mg disintegrating tablet*

Details

Criteria	Step Therapy requires trial of regular donepezil 5 mg or 10mg oral tablets in previous 120 days.
----------	--

2019 Chinese Community Health Plan Senior Select Program (HMO SNP)

Step Therapy Criteria
Updated 11/2019

DEXILANT_2019

Products Affected

Step 2:

- DEXILANT 30 MG CAPSULE, DELAYED RELEASE
- DEXILANT 60 MG CAPSULE, DELAYED RELEASE

Details

Criteria	Step therapy requires trial of lansoprazole in the previous 120 days.
----------	---

DRY EYE OTC (CCHP 2018)

Products Affected

Step 2:

- RESTASIS 0.05 % EYE DROPS IN A DROPPERETTE

Details

Criteria	Step Therapy requires trial of OTC artificial tears.
-----------------	--

OPHTHALMIC ANTI-INFECTIVES_NVT 2015

Products Affected

Step 2:

- BESIVANCE 0.6 % EYE DROPS,SUSPENSION
- *gatifloxacin 0.5 % eye drops*

Details

Criteria	Step Therapy requires trial of one of the following ciprofloxacin, levofloxacin, or ofloxacinin previous 120 days.
----------	--

PANCREATIC ENZYMES_NVT 2015

Products Affected

Step 2:

- PANCREAZE 10,500 UNIT-35,500 UNIT-61,500 UNIT CAPSULE,DELAYED RELEASE
- PANCREAZE 16,800 UNIT-56,800 UNIT-98,400 UNIT CAPSULE,DELAYED RELEASE
- PANCREAZE 2,600 UNIT-6,200 UNIT-10,850 UNIT CAPSULE,DELAYED RELEASE
- PANCREAZE 21,000 UNIT-54,700 UNIT-83,900 UNIT CAPSULE,DELAYED RELEASE
- PANCREAZE 4,200 UNIT-14,200 UNIT-24,600 UNIT CAPSULE,DELAYED RELEASE

Details

Criteria	Step Therapy requires trial of CREON in previous 120 days.
----------	--

PENTASA_NVT 2015

Products Affected

Step 2:

- APRISO 0.375 GRAM CAPSULE,EXTENDED RELEASE
- DELZICOL 400 MG CAPSULE (DR TABLETS INSIDE)
- LIALDA 1.2 GRAM TABLET,DELAYED RELEASE
- *mesalamine 400 mg capsule (with delayed release tablets inside)*

Details

Criteria	Step Therapy requires trial of one of the following: mesalamine delayed-release 1.2gm, or mesalamine DR 800 mg in previous 120 days.
----------	--

ST_RIVASTIGMINE_2019

Products Affected

Step 2:

- *rivastigmine 13.3 mg/24 hour transdermal patch*
- *rivastigmine 9.5 mg/24 hour transdermal patch*
- *rivastigmine 4.6 mg/24 hour transdermal patch*

Details

Criteria	Step Therapy requires trial of rivastigmine tablets in past 120 days.
----------	---

2019 Chinese Community Health Plan Senior Select Program (HMO SNP)

Step Therapy Criteria
Updated 11/2019

ST_SMOKINGCESS_2019

Products Affected

Step 2:

- ZYBAN 150 MG TABLET,EXTENDED RELEASE

Details

Criteria	Step therapy requires trial of Nicoderm patches in previous 120 days.
----------	---

ULORIC_NVT 2015

Products Affected

Step 2:

- *febuxostat 40 mg tablet*
- *febuxostat 80 mg tablet*
- ULORIC 40 MG TABLET
- ULORIC 80 MG TABLET

Details

Criteria	Step Therapy requires trial of allopurinol in previous 120 days.
----------	--

ZADITOR OTC (CCHP2017)

Products Affected

Step 2:

- *olopatadine 0.1 % eye drops*

Step 3:

- *olopatadine 0.2 % eye drops*
- PAZEO 0.7 % EYE DROPS

Details

Criteria	Step Therapy requires trial of OTC zaditor/ketotifen for olopatadine ophth soln. Trial of olopatadine 1 mg/ml ophth soln required for olopatadine 2 mg/ml and PAZEO
----------	---

2019 Chinese Community Health Plan Senior Select Program (HMO SNP)

Step Therapy Criteria

Updated 11/2019

INDEX

A

acyclovir 5 % topical ointment.....	1
ALPHAGAN P 0.1 % EYE DROPS	2
APRISO 0.375 GRAM	
CAPSULE,EXTENDED RELEASE.....	9

B

BESIVANCE 0.6 % EYE	
DROPS,SUSPENSION	7

D

DELZICOL 400 MG CAPSULE (DR	
TABLETS INSIDE)	9
DESVENLAFAXINE ER 100 MG	
TABLET,EXTENDED RELEASE 24 HR	
.....	3
DESVENLAFAXINE ER 50 MG	
TABLET,EXTENDED RELEASE 24 HR	
.....	3
DESVENLAFAXINE FUMARATE ER 100	
MG TABLET, EXTENDED RELEASE	
24 HR.....	3
DESVENLAFAXINE FUMARATE ER 50	
MG TABLET, EXTENDED RELEASE	
24 HR.....	3
DEXILANT 30 MG CAPSULE,	
DELAYED RELEASE.....	5
DEXILANT 60 MG CAPSULE,	
DELAYED RELEASE.....	5
donepezil 10 mg disintegrating tablet.....	4
donepezil 5 mg disintegrating tablet.....	4
duloxetine 40 mg capsule, delayed release...	3

E

EMSAM 12 MG/24 HR TRANSDERMAL	
24 HOUR PATCH.....	3
EMSAM 6 MG/24 HR TRANSDERMAL	
24 HOUR PATCH.....	3
EMSAM 9 MG/24 HR TRANSDERMAL	
24 HOUR PATCH.....	3

F

febuxostat 40 mg tablet.....	12
febuxostat 80 mg tablet.....	12
FETZIMA 120 MG	
CAPSULE,EXTENDED RELEASE.....	3

FETZIMA 20 MG (2)-40 MG (26)

CAPSULE,EXTENDED RELEASE,24	
HR,DOSE PACK.....	3
FETZIMA 20 MG CAPSULE,EXTENDED	
RELEASE.....	3
FETZIMA 40 MG CAPSULE,EXTENDED	
RELEASE.....	3
FETZIMA 80 MG CAPSULE,EXTENDED	
RELEASE.....	3
fluvoxamine er 100 mg capsule,extended	
release 24 hr.....	3
fluvoxamine er 150 mg capsule,extended	
release 24 hr.....	3

G

gatifloxacin 0.5 % eye drops	7
------------------------------------	---

L

LIALDA 1.2 GRAM TABLET,DELAYED	
RELEASE.....	9

M

MARPLAN 10 MG TABLET	3
mesalamine 400 mg capsule (with delayed	
release tablets inside).....	9

O

olopatadine 0.1 % eye drops.....	13
olopatadine 0.2 % eye drops.....	13

P

PANCREAZE 10,500 UNIT-35,500 UNIT-	
61,500 UNIT CAPSULE,DELAYED	
RELEASE.....	8
PANCREAZE 16,800 UNIT-56,800 UNIT-	
98,400 UNIT CAPSULE,DELAYED	
RELEASE.....	8
PANCREAZE 2,600 UNIT-6,200 UNIT-	
10,850 UNIT CAPSULE,DELAYED	
RELEASE.....	8
PANCREAZE 21,000 UNIT-54,700 UNIT-	
83,900 UNIT CAPSULE,DELAYED	
RELEASE.....	8
PANCREAZE 4,200 UNIT-14,200 UNIT-	
24,600 UNIT CAPSULE,DELAYED	
RELEASE.....	8
PAZEO 0.7 % EYE DROPS	13

2019 Chinese Community Health Plan Senior Select Program (HMO SNP)

Step Therapy Criteria
Updated 11/2019

R

RESTASIS 0.05 % EYE DROPS IN A DROPPERETTE	6
rivastigmine 13.3 mg/24 hour transdermal patch.....	10
rivastigmine 4.6 mg/24 hour transdermal patch.....	10
rivastigmine 9.5 mg/24 hour transdermal patch.....	10

T

TRINTELLIX 10 MG TABLET	3
TRINTELLIX 20 MG TABLET	3
TRINTELLIX 5 MG TABLET	3

U

ULORIC 40 MG TABLET.....	12
ULORIC 80 MG TABLET.....	12

V

VIIBRYD 10 MG (7)-20 MG (23) TABLETS IN A DOSE PACK	3
VIIBRYD 10 MG TABLET.....	3
VIIBRYD 20 MG TABLET	3
VIIBRYD 40 MG TABLET.....	3

Z

ZYBAN 150 MG TABLET,EXTENDED RELEASE.....	11
--	----